Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Empagliflozin on Urinary Excretion of Adenosine and on Markers of Osteocyte Function and Glomerular Damage in Diabetic and Non-diabetic Patients With Chronic Kidney Disease

NCT04961931 is registered in ClinicalTrials.gov with Medical University of Lodz as lead sponsor.

NCT NCT04961931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04961931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Empagliflozin on Urinary Excretion of Adenosine and on Markers of Osteocyte Function and Glomerular Damage in Diabetic and Non-diabetic Patients With Chronic Kidney Disease
Lead sponsor
Medical University of Lodz
Phase
Not applicable
Overall status
Unknown status
Start date
January 1, 2019
Completion date
August 31, 2021
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease stage3